natgillin/translations-raw huggingface dataset:
Consistent with the above results, in a meta analysis including 6 studies of 335 clopidogrel-treated subjects at steady state, it was shown that active metabolite exposure was decreased by 28% for intermediate metabolisers, and 72% for poor metabolisers while platelet aggregation inhibition (5 μM ADP) was decreased with differences in IPA of 5.9% and 21.4%, respectively, when compared to extensive metabolisers. 
V skladu z zgornjimi rezultati so izsledki metaanalize, ki je zajela 6 študij, s 335 bolniki, zdravljenih s klopidogrelom, v stanju dinamičnega ravnovesja, pokazali, da se je v primerjavi z obsežnimi metabolizatorji izpostavljenost aktivnemu presnovku pri srednje dobrih metabolizatorjih zmanjšala za 28 %, pri slabih metabolizatorjih se je zmanjšala za 72 %, zavrtje agregacije trombocitov (5 µM ADP) pa se je zmanjšalo, in sicer z razliko pri IPA v višini 5,9 % oziroma 21,4 % v primerjavi z dobrimi metabolizatorji.
Rare side effect (may affect up to 1 in 1000 people): • vertigo. 
Redki neželeni učinki (pojavijo se lahko pri največ 1 od 1.000 bolnikov): • vrtoglavica.
Do NOT take Clopidogrel/Acetylsalicylic acid Teva during third trimester of pregnancy. 
Zdravila Klopidogrel/acetilsalicilna kislina Teva NE smete jemati v tretjem tromesečju nosečnosti.
As a dual antiplatelet agent, the combination of clopidogrel/acetylsalicylic acid should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with other NSAIDs including Cox-2 inhibitors, heparin, glycoprotein IIb/IIIa inhibitors, selective serotonin reuptake inhibitors (SSRIs), or thrombolytics. 
Kombinacijo klopidogrela/acetilsalicilne kisline, kot dvojno antiagregacijsko sredstvo, je treba previdno uporabljati pri bolnikih s povečanim tveganjem za krvavitev zaradi poškodbe, kirurškega posega ali drugih patoloških stanj ter pri bolnikih, ki so zdravijo z drugimi nesteroidnimi protivnetnimi zdravili, vključno z zaviralci Cox-2, heparinom, zaviralci glikoproteina IIb/IIIa, selektivnimi zaviralci ponovnega privzema serotonina ali trombolitiki.
Colitis (including ulcerative or lymphocytic colitis) 
Kolitis (vključno z ulceroznim ali limfocitnim kolitisom).
If you are breast-feeding or planning to breast-feed, talk to your doctor before taking this medicine. 
Če dojite ali načrtujete dojenje, se pred uporabo tega zdravila posvetujte s svojim zdravnikom.
Clopidogrel/Acetylsalicylic acid Teva contains clopidogrel and acetylsalicylic acid (ASA) and belongs to a group of medicines called antiplatelet medicinal products. 
Zdravilo Klopidogrel/acetilsalicilna kislina Teva vsebuje klopidogrel in acetilsalicilno kislino (ASA) in spada v skupino zdravil, ki se imenujejo zaviralci agregacije trombocitov.
• excessive gas in stomach or intestines 
• napihnjenost v želodcu ali črevesju,
Subsequently a respiratory acidosis occurs as a result of a suppressive effect on the respiratory centre. 
Posledično se zaradi supresivnega učinka na dihalni center pojavi respiratorna acidoza.
Acetylsalicylic acid inhibits platelet aggregation by irreversible inhibition of prostaglandin cyclo-oxygenase and thus inhibits the generation of thromboxane A2, an inducer of platelet aggregation and vasoconstriction. 
Acetilsalicilna kislina zavira agregacijo trombocitov z ireverzibilnim zavrtjem prostaglandinske ciklooksigenaze in s tem zavira nastajanje tromboksana A2, ki inducira agregacijo trombocitov in vazokonstrikcijo.
Moreover, the safety profile of clopidogrel in this subgroup of patients did not raise any particular concern. 
Poleg tega, pri tej podskupini bolnikov niso ugotovili nobenih posebnih težav z varnostjo klopidogrela.
The combination of clopidogrel/acetylsalicylic acid has no or negligible influence on the ability to drive and use machines. 
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Kombinacija klopidogrela/acetilsalicilna kisline ne vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
As a precaution concomitant use of strong or moderate CYP2C19 inhibitors should be discouraged (see sections 4.4 and 5.2). 
Iz previdnosti, se sočasno uporabo močnih ali srednje močnih zaviralcev CYP2C19 odsvetuje (glejte poglavji 4.4 in 5.2).
What you need to know before you take Clopidogrel/Acetylsalicylic acid Teva 
Kaj morate vedeti, preden boste vzeli zdravilo Klopidogrel/acetilsalicilna kislina Teva
You should not breast-feed while using this medicine. 
Tega zdravila ne smete jemati med obdobjem dojenja.
The marketing authorisation holder shall submit PSURs for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 
Imetnik dovoljenja za promet z zdravilom mora redno posodobljena poročila o varnosti zdravila za to zdravilo predložiti v skladu z zahtevami, določenimi v seznamu referenčnih datumov Unije (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES in objavljenem na evropskem spletnem portalu o zdravilih.
What Clopidogrel/Acetylsalicylic acid Teva is and what it is used for 
Kaj je zdravilo Klopidogrel/acetilsalicilna kislina Teva in za kaj ga uporabljamo
Clopidogrel/Acetylsalicylic acid Teva is a fixed-dose combination medicinal product for continuation of therapy in: 
Zdravilo Klopidogrel/acetilsalicilna kislina Teva je kombinirano zdravilo s stalnim odmerkom za nadaljevalno zdravljenje pri:
GI undesirable effects including stomach pain, heartburn, nausea, vomiting, and GI bleeding may occur. 
Pojavijo se lahko gastrointestinalni neželeni učinki, vključno z bolečino v želodcu, zgago, navzeo, bruhanjem in krvavitvijo v prebavila.
Yellow, film-coated capsule shaped tablets. 
filmsko obložena tableta (tableta) Rumene, filmsko obložene tablete v obliki kapsule.
How to store Clopidogrel/Acetylsalicylic acid Teva Contents of the pack and other information 
Shranjevanje zdravila Klopidogrel/acetilsalicilna kislina Teva Vsebina pakiranja in dodatne informacije
- For more than 12 hours: patients should take the next dose at the regular scheduled time and should not double the dose. 
- če je zamuda več kot 12 ur, naj bolnik naslednji odmerek vzame ob običajnem času in naj ne vzame dvojnega odmerka.
The most common side effect which has been seen with Clopidogrel/Acetylsalicylic acid Teva is bleeding. 
Najpogostejši neželeni učinek med zdravljenjem z zdravilom Klopidogrel/acetilsalicilna kislina Teva so krvavitve.
Fifteen percent (15.0%) of patients in the clopidogrel plus ASA group and 21.7% in the group treated with ASA alone reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favor of clopidogrel (95% CI: 24, 47%; p <0.001), mainly related to a reduction in occluded infarct-related arteries. 
Primarni opazovani dogodek je bil opažen pri 15,0 % bolnikov v skupini, ki je prejemala klopidogrel in ASA ter 21¸7 % bolnikov v skupini, ki je prejemala samo ASA, kar predstavlja absolutno zmanjšanje za 6,7 % in 36 % zmanjšanje verjetnosti v prid klopidogrela (95% IZ: 24%, 47 %; p<0,001) v glavnem zaradi zmanjšanja zaradi infarkta zamašenih arterij.
- inhibition of uterine contractions resulting in delayed or prolonged labour. 
- zavrtju krčenja maternice in posledično odloženemu ali podaljšanemu porodu.
NAME OF THE MARKETING AUTHORISATION HOLDER Teva Pharma B.V. 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Teva Pharma B.V.
The combination of clopidogrel/acetylsalicylic acid should be used with caution in patients who receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4). 
Kombinacijo klopidogrela/acetilsalicilne kisline morate uporabljati previdno pri bolnikih, ki se sočasno zdravijo z zaviralci glikoproteina IIb/IIIa (glejte poglavje 4.4).
Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) plus ASA (75-325 mg once daily) or ASA alone (N=6,303), (75-325 mg once daily) and other standard therapies. 
Bolniki so bili naključno razporejeni v skupino, ki je prejemala klopidogrel (začetni odmerek 300 mg, nato pa 75 mg/dan, N=6.259) in ASA (75 do 325 mg enkrat na dan) ali samo ASA (N=6.303), (75 do 325 mg enkrat na dan) in drugimi standardnimi terapijami.
• heparin or any other injectable medicine used to reduce blood clotting, 
• heparin ali drugo zdravilo v obliki injekcij proti strjevanju krvi,
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel plus ASA group and 1,187 (18.8%) in the ASA group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel plus ASA group. 
Število bolnikov s primarnim opazovanim dogodkom (SŽ smrt, MI, kap ali refraktorno ishemijo) je bilo 1.035 (16,5 %) v skupini, zdravljeni s klopidogrelom in z ASA in 1.187 (18,8 %) v skupini, zdravljeni z ASA, kar je 14 % zmanjšanje relativnega tveganja (95 % IZ od 6 % do 21 %, p=0,0005) za skupino, zdravljeno s klopidogrelom in z ASA.
Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of medicinal products that inhibit the activity of this enzyme would be expected to result in reduced drug levels of the active metabolite of clopidogrel. 
Glede na to, da se klopidogrel v aktivni presnovek deloma presnovi s CYP2C19, je mogoče pričakovati, da uporaba zdravil, ki zavrejo delovanje tega encima, zmanjša koncentracijo aktivnega presnovka klopidogrela.
This effect lasts for the life of the platelet. 
Učinek traja celotno življenjsko dobo trombocita.
Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction in terms of major cardiovascular events have been reported from both observational and clinical studies. 
V opazovalnih in kliničnih študijah so poročali o razhajajočih se podatkih o kliničnih posledicah tega farmakokinetičnega/farmakodinamskega medsebojnega delovanja, z vidika večjih kardiovaskularnih dogodkov.
Clopidogrel/Acetylsalicylic acid Teva is used following initiation of therapy with clopidogrel and ASA given separately. 
Zdravilo Klopidogrel/acetilsalicilna kislina Teva se uporablja po začetni terapiji s klopidogrelom in z ASA, ki ju bolnik prejema ločeno:
• probenecid, benzbromarone, or sulfinpyrazone, medicines used to treat gout, 
• probenecid, benzbromaron ali sulfinpirazon, zdravila za zdravljenje protina,
Clopidogrel/Acetylsalicylic acid Teva contains lactose. 
Zdravilo Klopidogrel/acetilsalicilna kislina Teva vsebuje laktozo.
Film-coated tablet 14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 
filmsko obložena tableta 14 filmsko obloženih tablet 28 filmsko obloženih tablet 30 filmsko obloženih tablet
Patients received clopidogrel (75 mg/day, n=22,961) plus ASA (162 mg/day), or ASA alone (162 mg/day) (n=22,891), for 28 days or until hospital discharge. 
Bolniki so 28 dni oziroma do odpusta dobivali klopidogrel (75 mg/dan, n=22.961) in ASA (162 mg/dan) ali samo ASA (162 mg/dan, n=22.891).
Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1,752) plus ASA or ASA alone (n=1,739), (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin. 
Bolniki so prejemali klopidogrel (300 mg začetni odmerek, nato pa 75 mg/dan, n=1.752) in ASA ali samo ASA (n=1.739), (150 mg do 325 mg kot začetni odmerek, nato 75 mg do 162 mg/dan), fibrinolitično sredstvo in po potrebi heparin.
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, granulocytopenia, anaemia, acquired haemophilia A. 
Trombotična trombocitopenična purpura (TTP) (glejte poglavje 4.4), aplastična anemija, pancitopenija, agranulocitoza, huda trombocitopenija, granulocitopenija, anemija, pridobljena hemofilija A
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day. 
Po večkratnih odmerkih 75 mg klopidogrela na dan, je bilo pri osebah s hudo ledvično boleznijo (očistek kreatinina od 5 do 15 ml/min) zaviranje z ADP sprožene agregacije trombocitov manjše (25 %) od tiste, opažene pri zdravih osebah.
Omeprazole 80 mg once daily administered either at the same time as clopidogrel or with 12 hours between the administrations of the two drugs decreased the exposure of the active metabolite by 45% (loading dose) and 40% (maintenance dose). 
Pri sočasni uporabi omperazola 80 mg/dan in klopidogrela ali v presledku 12 ur, se je izpostavljenost aktivnemu presnovku klopidogrela zmanjšala za 45 % (začetni odmerek) oz. 40 % (vzdrževalni odmerek).
White HDPE multi-layer bottles and green polypropylene (PP) child-resistant closures with dessicant. 
Bele večplastne plastenke iz polietilena visoke gostote (HDPE) z zelenimi za otroke varnimi zaporkami iz polipropilena (PP) s sušilnim sredstvom.
• fluoxetine, fluvoxamine, or moclobemide, medicines to treat depression, 
• fluoksetin, fluvoksamin ali moklobemid, zdravila za zdravljenje depresije,
There are no fertility data with the combination of clopidogrel/acetylsalicylic acid. 
Podatkov o plodnosti za kombinacijo klopidogrela/acetilsalicilna kisline ni.
Clopidogrel/Acetylsalicylic acid Teva is supplied in blisters in pack sizes of 14, 28 and 30 film-coated tablets or in bottles in a pack size of 30 film-coated tablets. 
Zdravilo Klopidogrel/acetilsalicilna kislina Teva je na voljo v pretisnih omotih v pakiranjih po 14, 28 in 30 filmsko obloženih tablet ali v plastenkah v pakiranju po 30 filmsko obloženih tablet.
• ST segment elevation acute myocardial infarction in medically treated patients eligible for 
• akutnem miokardnem infarktu z elevacijo ST spojnice pri bolnikih, ki se zdravijo z zdravili in so primerni za trombolitično zdravljenje.
White HDPE bottles and green polypropylene (PP) child-resistant closures with dessicant. 
Bele plastenke iz polietilena visoke gostote (HDPE) z zelenimi za otroke varnimi zaporkami iz polipropilena (PP) s sušilnim sredstvom.
Clopidogrel/Acetylsalicylic acid Teva is supplied in blisters in pack sizes of 10, 14, 28, 30, 50, 90 and 100 film-coated tablets or in bottles in a pack size of 30 film-coated tablets. 
Zdravilo Klopidogrel/acetilsalicilna kislina Teva je na voljo v pretisnih omotih v pakiranjih po 10, 14, 28, 30, 50, 90 in 100 filmsko obloženih tablet ali v plastenkah v pakiranju po 30 filmsko obloženih tablet.
Although minor upper GI symptoms, such as dyspepsia, are common and can occur anytime during therapy, physicians should remain alert for signs of ulceration and bleeding, even in the absence of previous GI symptoms. 
dispepsija, so pogosti in se lahko pojavijo kadarkoli med zdravljenjem, zato morajo zdravniki ostati pozorni na gastrointestinalne znake razjede in krvavitve, četudi bolnik pred tem ni imel takšnih simptomov.
• ticlopidine, other antiplatelet agent. 
• tiklopidin, drugo antiagregacijsko zdravilo.
In CURE there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery. 
V študiji CURE pri bolnikih, ki so imeli narejeno koronarno premostitev in so pred tem jemali klopidogrel in ASA, v 7 dneh po operaciji niso ugotovili čezmernega števila hujših krvavitev, če so to zdravljenje prekinili vsaj pet dni pred operacijo.
Furthermore, the pharmacodynamic activity of clopidogrel was not significantly influenced by the co-administration of phenobarbital or oestrogen. 
Poleg tega na farmakodinamično aktivnost klopidogrela sočasna uporaba fenobarbitala ali estrogena ni pomembno vplivala.
Acute liver failure, liver injury, mainly hepatocellular*, hepatitis, elevation of hepatic 
Akutna odpoved jeter, poškodba jeter, predvsem hepatocelularna*, hepatitis, zvišane vrednosti jetrnih encimov*, nenormalni testi jetrne funkcije
The combination of clopidogrel/acetylsalicylic acid must not be used in patients with severe hepatic impairment (see section 4.3). 
Kombinacija klopidogrela/acetilsalicilne kisline se ne sme uporabljati pri bolnikih s hudo okvarjenim delovanjem jeter (glejte poglavje 4.3).
Interactions with the following medicinal products with higher (anti-inflammatory) doses of ASA have also been reported: angiotensin converting enzyme (ACE) inhibitors, acetazolamide, anticonvulsants (phenytoin and valproic acid), beta blockers, diuretics, and oral hypoglycemic agents. 
Med uporabo večjih (protivnetnih) odmerkov ASA so poročali o interakcijah z naslednjimi zdravili: zaviralci angiotenzin konvertaze (ACE), acetazolamidom, antiepileptiki (fenitoin in valprojska kislina), zaviralci adrenergičnih receptorjev beta, diuretiki in peroralnimi hipoglikemiki.
Clopidogrel was found to have no effect on the fertility of male and female rats and was not teratogenic in either rats or rabbits. 
Ugotovili so, da klopidogrel nima vpliva na plodnost podganjih samcev in samic.
Clopidogrel has been evaluated for safety in more than 42,000 patients who have participated in clinical studies, including over 30,000 patients treated with clopidogrel plus ASA, and over 9,000 patients treated for 1 year or more. 
Več kot 30.000 teh bolnikov je prejemalo kombinacijo klopidogrela in ASA, pri več kot 9.000 pa je zdravljenje trajalo 1 leto ali več.
The safety of the concomitant administration of the combination of clopidogrel/acetylsalicylic acid with other thrombolytic agents has not been formally established and should be undertaken with caution (see section 4.4). 
Varnost sočasne uporabe kombinacije klopidogrela/acetilsalicilne kisline z drugimi trombolitiki ni bila formalno ugotovljena, zato je pri njihovi sočasni uporabi potrebna previdnost (glejte poglavje 4.4).
• The other ingredients are: Tablet core: lactose monohydrate, microcrystalline cellulose, hydroxypropylcellulose 100 cP, crospovidone (type A), stearic acid, croscarmellose sodium, hydrogenated vegetable oil and sodium lauril sulfate. 
Jedro tablete: laktoza monohidrat, mikrokristalna celuloza, hidroksipropilceluloza 100 cP, krospovidon (tip A), stearinska kislina, premrežen natrijev karmelozat, hidrogenirano rastlinsko olje in natrijev lavrilsulfat.
The Cmax of the active metabolite is twice as high following a single 300 mg clopidogrel loading dose as it is after four days of 75 mg maintenance dose. 
Cmax aktivnega presnovka je po enem 300 mg začetnem odmerku klopidogrela dvakrat večja kot po štirih dneh uporabe vzdrževalnega odmerka 75 mg. Cmax je dosežena približno 30 do 60 minut po odmerjanju.
Serious haemorrhage, haemorrhage of operative wound, vasculitis, hypotension 
Resne krvavitve, krvavitve operacijske rane, vaskulitis, hipotenzija
The concomitant administration of the combination of clopidogrel/acetylsalicylic acid with oral anticoagulants is not recommended since it may increase the intensity of bleeding (see section 4.4). 
Sočasna uporaba kombinacije klopidogrela/acetilsalicilne kisline s peroralnimi antikoagulanti ni priporočljiva, ker lahko poveča intenzivnost krvavitev (glejte poglavje 4.4).
After first opening the bottle use within 30 days. 
Porabiti v 30 dneh po prvem odprtju plastenke.
Clopidogrel is a prodrug, one of whose metabolites is an inhibitor of platelet aggregation. 
Klopidogrel je predzdravilo, eden njegovih presnovkov pa zavira agregacijo trombocitov.
If a dose is missed: - Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time. 
Če bolnik izpusti odmerek: - če je zamuda manj kot 12 ur po običajnem času za odmerek, naj bolnik odmerek vzame takoj,
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia). 
Pri 2.172 bolnikih (17 % vseh bolnikov, vključenih v študijo CURE), katerim je bil vstavljen stent (Stent-CURE), so podatki post-hoc analize še posebej pokazali, da je klopidogrel v primerjavi s placebom pri sestavljenem primarnem opazovanem dogodku (SŽ smrt, MI, kap) pomembno zmanjšal relativno tveganje za 26,2 %.
• if you have a risk of bleeding such as: a medical condition that puts you at risk of internal bleeding (such as a stomach ulcer). 
• če je pri vas prisotno tveganje za krvavitev, kot na primer: bolezen, zaradi katere ste v nevarnosti za notranjo krvavitev (npr. razjeda na želodcu), krvna motnja, zaradi katere ste bolj nagnjeni k notranji krvavitvi (krvavitev v katerakoli tkiva, organe ali sklepe v telesu),
Lactose monohydrate Microcrystalline cellulose Hydroxypropylcellulose 100 cP Crospovidone (type A) Stearic Acid 
Jedro tablete: laktoza monohidrat mikrokristalna celuloza hidroksipropilceluloza 100 cP krospovidon (tip A) stearinska kislina premrežen natrijev karmelozat hidrogenirano rastlinsko olje natrijev lavrilsulfat
Polydextrose 
Trombolitiki
Subsequent metabolism of the 2-oxo-clopidogrel intermediate metabolite results in formation of the active metabolite, a thiol derivative of clopidogrel. 
2-oksoklopidogrela povzroči nastanek aktivnega presnovka, ki je tiolski derivat klopidogrela.
The ASA in the combination of clopidogrel/acetylsalicylic acid is rapidly hydrolyzed in plasma to salicylic acid, with a half-life of 0.3 to 0.4 hours for ASA doses from 75 to 100 mg. Salicylic acid is primarily conjugated in the liver to form salicyluric acid, a phenolic glucuronide, an acyl glucuronide, and a number of minor metabolites. 
ASA iz kombinacije klopidogrela/acetilsalicilne kisline v plazmi hitro hidrolizira v salicilno kislino, z razpolovnim časom od 0,3 do 0,4 ure za odmerke od 75 do 325 mg ASA.
• muscular pain 
• bolečine v mišicah,
Non-cardiogenic pulmonary edema can occur with acute and chronic acetylsalicylic acid overdose (see section 4.8). 
Zaradi akutnega ali kroničnega prevelikega odmerjanja acetilsalicilne kisline se lahko pojavi nekardiogeni pljučni edem (glejte poglavje 4.8).
Very rare, not known colitis (including ulcerative or lymphocytic colitis), upper gastro-intestinal symptoms* such as gastralgia (see section 4.4), stomatitis. 
Zelo redki, neznana npr. gastralgija (glejte poglavje 4.4), stomatitis.
Therefore, concomitant use should be undertaken with caution (see section 
Zato moramo biti pri sočasni uporabi previdni (glejte poglavje 4.4).
Acquired haemophilia has been reported following use of clopidogrel. 
Poročali so o pojavu pridobljene hemofilije po uporabi klopidogrela.
ASA is known to be excreted in limited amounts in human milk. 
Znano je, da se pri človeku ASA izloča v materino mleko.
No substantial differences in active metabolite exposure and mean inhibition of platelet aggregation (IPA) were observed between ultrarapid, extensive and intermediate metabolisers. 
Med ultra hitrimi, obsežnimi in srednje dobrimi metabolizatorji niso ugotovili bistvenih razlik v izpostavljenosti aktivnemu presnovku in povprečnem zavrtju agregacije trombocitov (IPA).
Clopidogrel/Acetylsalicylic acid Teva should be given as a single daily 75 mg/75 mg dose. 
Zdravilo Klopidogrel/acetilsalicilna kislina Teva se mora dajati kot enkratni dnevni odmerek 75 mg/75 mg.
• nausea (feeling sick) 
• navzea (siljenje na bruhanje),
The concomitant administration of the combination of clopidogrel/acetylsalicylic acid with oral anticoagulants is not recommended since it may increase the intensity of bleeding (see section 4.5). 
Sočasna uporaba kombinacije klopidogrela/acetilsalicilne kisline in peroralnih koagulantov ni priporočljiva, ker lahko poveča jakost krvavitev (glejte poglavje 4.5).
• If you suffer from severe liver disease. 
• če imate hudo bolezen ledvic,
Clopidogrel/Acetylsalicylic acid Teva should be given as a single daily 75 mg/100 mg dose. 
Zdravilo Klopidogrel/acetilsalicilna kislina Teva se mora dajati kot enkratni dnevni odmerek 75 mg/100 mg.